Boston, Massachusetts
Cancer surgery and procedure trials in Boston, MA
52 cancer surgery and procedure studies are recruiting participants at sites in Boston as of November 18, 2026, according to ClinicalTrials.gov. Cancer Surgery Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Boston at a glance
- 52 studies are recruiting at a site in Boston.
- By phase: Phase 1 (6), Phase 1/2 (4), Phase 2 (16), Phase 3 (14), Phase 4 (1), No phase (8), Observational (3). Studies of devices and behavioral approaches have no phase.
- By sponsor: university, hospital or other (32), government (17), industry (3).
- By research area: Breast Cancer (16), Lymphoma (16), Lung Cancer (10), Melanoma (4), Pancreatic Cancer (3), Prostate Cancer (3).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Boston
Basic details from each study's public record (the 30 most recently updated of 52). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
- Phase 1
- Ages 12 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT05372640 · updated
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT05422794 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Dana-Farber Cancer Institute · Tufts Medical Center
- Registry record
- NCT05564377 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Tufts Medical Center
- Registry record
- NCT06058377 · updated
Distance-Based Exercise to Preserve Function and Prevent Disability
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT07059884 · updated
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- University Hospital, Basel, Switzerland
- Study site
- Harvard Medical School
- Registry record
- NCT05890677 · updated
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT07137416 · updated
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT06876714 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Boston, MA on ClinicalTrials.gov.
Lung cancer studies recruiting in Boston
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT04665739 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Beth Israel Deaconess Medical Center · Boston Medical Center · Dana-Farber Cancer Institute
- Registry record
- NCT04267848 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Tufts Medical Center
- Registry record
- NCT06096844 · updated
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Massachusetts General Hospital Cancer Center
- Registry record
- NCT03191149 · updated
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- VA Office of Research and Development
- Study site
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
- Registry record
- NCT02984761 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Boston, MA on ClinicalTrials.gov.
Prostate cancer studies recruiting in Boston
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- NRG Oncology
- Study sites
- Brigham and Women's Hospital · Dana-Farber Cancer Institute
- Registry record
- NCT05946213 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Boston, MA on ClinicalTrials.gov.
Melanoma studies recruiting in Boston
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT06585410 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Boston, MA on ClinicalTrials.gov.
Lymphoma studies recruiting in Boston
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Phase 2
- Up to 365 days
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT06317662 · updated
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Phase 1/2
- Up to age 22
- All sexes
- Sponsor
- PedAL BCU, LLC
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT04726241 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Dana-Farber Cancer Institute · Tufts Medical Center
- Registry record
- NCT04269902 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT05675410 · updated
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- Phase 3
- Ages 12 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Dana-Farber Cancer Institute · Massachusetts General Hospital Cancer Center · Tufts Medical Center
- Registry record
- NCT07215910 · updated
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Phase 3
- Ages 65 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Beth Israel Deaconess Medical Center · Dana-Farber Cancer Institute
- Registry record
- NCT07321652 · updated
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- From 366 days, up to 46 years
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT06124157 · updated
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- Phase 2
- Ages 18 to 75
- All sexes
- Sponsor
- City of Hope Medical Center
- Study site
- DFCI/BWH Brigham and Women's Hospital
- Registry record
- NCT06059391 · updated
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Phase 1
- Ages 18 to 75
- All sexes
- Sponsor
- City of Hope Medical Center
- Study site
- Brigham and Women's Hospital
- Registry record
- NCT07020533 · updated
GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Massachusetts General Hospital
- Study site
- Massachusetts General Hospital
- Registry record
- NCT07711483 · updated
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT07061951 · updated
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Phase 1/2
- From 12 months, up to 21 years
- All sexes
- Sponsor
- Children's Oncology Group
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT04870944 · updated
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- University of Washington
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT06745076 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Boston, MA on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Boston
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT05372614 · updated
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
- Observational
- Up to age 17
- All sexes
- Sponsor
- M.D. Anderson Cancer Center
- Study site
- Boston Children's Hospital
- Registry record
- NCT06651580 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Boston, MA on ClinicalTrials.gov.
Ask about studies near Boston
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a surgery or another procedure, as each study is coded in the registry.
Cancer Surgery Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections